These findings reveal a previously unrecognized mechanism governing graft survival and suggest that optimizing mechanical properties of biomaterial scaffolds or directly targeting Piezo1‐dependent mechanotransduction could substantially improve outcomes of cell‐based therapies for neurological disorders. This evidence concerns the gene PIEZO1 and nervous system disorder.